Clovis Oncology (CLVS) Surges: Stock Gains 7.3% in Session - Analyst Blog

By Zacks Equity Research,

Shutterstock photo

Clovis Oncology, Inc. ( CLVS ) was a big mover last session, as the company saw its shares rise by over 7% on the day. The move came on the back of solid volume too, as far more shares changed hands than in a normal session. The uptrend is continuing for this biotechnology company, as the stock rose nearly 8% in the past one-month time period.

The company has seen a mixed track record when it comes to estimate revisions over the past few weeks (1 increase, 2 decreases) and the earnings consensus hasn't been in trend either. This recent price action is certainly encouraging, so make sure to keep a close watch on this firm in the near future.

Clovis Oncology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Some better performing biotechnology stocks include Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ). All these carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

AFFYMETRIX INC (AFFX): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Stocks: AFFX , BIIB , CLVS , GILD

More from


Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by